Remidio Innovative Solutions has received official approval from India’s Central Drugs Standard Control Organisation (CDSCO) for its AI-based diagnostic tools aimed at detecting glaucoma and age-related macular degeneration (AMD). The latest approvals build on the success of Remidio’s earlier AI tool for diabetic retinopathy, which has screened nearly 250,000 patients over the past year.
Expanding Access to Vision Care in Remote Regions
The newly approved AI solutions are designed to operate without internet connectivity, making them highly suitable for deployment in rural and remote areas where access to specialised eye care services is limited.
Early Detection for Glaucoma and AMD
The Medios HI Glaucoma AI tool analyses critical parts of the eye to identify early signs of glaucoma, presenting results through intuitive heat maps. This advancement addresses a pressing need, as research shows that a significant majority of glaucoma cases in India remain undiagnosed, often leading to irreversible vision loss.
Also read: Tulu Health Unveils WhatsApp-Integrated AI Agent Platform
Similarly, the Medios HI AMD AI tool enables early detection of AMD, a leading cause of vision impairment in older adults. The AI system highlights abnormalities in retinal images, allowing healthcare providers to recommend timely specialist care.
Portable AI-Enabled Device for Rapid Screening
Both AI tools have been extensively tested in hospital and clinical environments, demonstrating high levels of accuracy. They are integrated into Remidio’s portable FOP NM 10 eye camera device, enabling rapid screening for glaucoma, AMD, and diabetic retinopathy with a single tap. By prioritising offline functionality and portability, Remidio is advancing efforts to bridge gaps in vision care access, particularly for underserved populations.
